FINNENCE ▪ THE WIRE FILE
THE WIRE · № 56295
Price move▼ Bearish
Johnson & Johnson -1.6%
KINDPrice move
DIRECTION▼ Bearish
SOURCES1
ENTITIES3
STORY SIZESTANDALONE
FIRST SEEN2026-09-30 01:52 UTC
LAST UPDATE2026-09-30 01:52 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
J&J weakness reflects litigation or pharma-pricing pressure on defensive healthcare.
Healthcare defensive under mild pressure
CATALYST TO WATCH
Litigation or drug-pricing headlines
MAIN RISK
Defensive rotation could lift it back
FULL DISPATCH
Johnson & Johnson (JNJ) moved -1.6% in the latest period (1d). Close: 267.57, prior: 271.95.
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
Merger would create one of Minnesota’s largest health systems2026-09-29 14:52 UTC
Merger would create one of Minnesota’s largest health systems2026-09-29 14:52 UTC
→CORRELATIONshares Healthcare
MNA president weighs in on Essentia Health and HealthPartners merger2026-09-30 02:25 UTC
MNA president weighs in on Essentia Health and HealthPartners merger2026-09-30 02:25 UTC
←CORRELATIONshares Healthcare
Merger would create one of Minnesota’s largest health systems2026-09-29 14:52 UTC
Merger would create one of Minnesota’s largest health systems2026-09-29 14:52 UTC
←CORRELATIONshares Healthcare, XLV
Health tech's dealmaking boom is back as firms chase scale and profitable growth2026-09-29 16:00 UTC
Health tech's dealmaking boom is back as firms chase scale and profitable growth2026-09-29 16:00 UTC
←CORRELATIONshares Healthcare
MN Attorney General promises public meetings on hospital merger and explains process2026-09-29 21:24 UTC
MN Attorney General promises public meetings on hospital merger and explains process2026-09-29 21:24 UTC
←CORRELATIONshares Healthcare
Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes2026-09-29 22:00 UTC
Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes2026-09-29 22:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.